Business Context and Reporting Period
This Form 8-K, dated June 15, 2021, reports the completion of a merger between Obalon Therapeutics, Inc. (the "Company") and ReShape Lifesciences Inc. ("ReShape"). Following the transaction, the Company was renamed ReShape Lifesciences Inc. and ReShape became a wholly-owned subsidiary named ReShape Weightloss Inc. The combined entity began trading on the NASDAQ Capital Market under the symbol "RSLS" on June 16, 2021.
Key Financial Metrics and Capital Structure
The filing details the capital structure adjustments resulting from the merger but does not provide consolidated revenue, profit, or cash flow metrics for the combined entity.
- Exchange Ratio: ReShape common and Series B preferred stockholders received 0.5637 shares of Company common stock (post-reverse split) per share, plus cash for fractional shares.
- Series C Preferred Stock: The Company assumed ReShape's Series C obligations, issuing 95,388 shares of new Company Series C Preferred Stock with an aggregate liquidation preference of approximately $26.2 million.
- Conversion Rights: The new Series C Preferred Stock is convertible into a total of 38 shares of Common Stock.
- Reverse Stock Split: The Company effected a 1-for-3 reverse stock split of its common stock to comply with NASDAQ minimum bid price requirements.
Material Changes Versus Prior Period
The primary material change is the corporate restructuring via merger, which fundamentally altered the Company's asset base, equity structure, and corporate identity.
- Corporate Name: Changed from Obalon Therapeutics, Inc. to ReShape Lifesciences Inc.
- Trading Symbol: Changed from "OBLN" to "RSLS".
- Board Composition: The entire prior board of directors resigned. Five new directors were elected, all previously serving on the ReShape board.
- Executive Leadership: Barton P. Bandy was appointed President and CEO, and Thomas Stankovich was appointed CFO and Secretary, replacing the prior leadership team.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or management commentary regarding future revenue or earnings projections.
- NASDAQ Listing Conditions: Continued listing is subject to conditions, including advance approval of financing transactions by independent directors and timely filing of Listing of Additional Shares (LAS) notifications to avoid immediate delisting.
- Preferred Stock Rights: Holders of the new Series C Preferred Stock possess significant protective rights, including the ability to block changes to their rights, amendments to charter documents, or the issuance of senior stock without their affirmative vote.
- Legal Disclaimer: Representations and warranties in the Merger Agreement are subject to qualifications and may not reflect factual information for investors.
Investor Verification Checklist
- Verify the post-merger share count and dilution impact of the 0.5637 exchange ratio and the issuance of Series C Preferred Stock.
- Confirm the specific terms of the Series C Preferred Stock liquidation preference ($26.2 million) and its conversion mechanics (38 shares total).
- Review the new Board of Directors' compensation program and independence status.
- Monitor compliance with NASDAQ listing conditions, specifically regarding financing approvals and LAS filings.
- Examine the full text of the Merger Agreement (Exhibit 2.1) and Series C Certificate of Designation (Exhibit 3.3) for detailed rights and limitations.